Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors

被引：4

作者：

Cheng, Hengmiao ^{[1
]}

Li, Puhui ^{[1
]}

Chen, Ping ^{[1
]}

Irimia, Adriana ^{[1
]}

Bae, Jae Hyun ^{[1
]}

Brooun, Alexei ^{[1
]}

Fagan, Patrick ^{[1
]}

Lam, Richard ^{[1
]}

Lin, Bingzhen ^{[1
]}

Zhang, Jingchuan ^{[1
]}

Zhan, Xuejun ^{[2
]}

Wu, Xu ^{[2
]}

Xie, Nan ^{[3
]}

Chiang, Gary ^{[1
]}

Shoemaker, Robert ^{[1
]}

Vernier, Jean-Michel ^{[1
]}

机构：

[1] Erasca Inc, San Diego, CA 92121 USA

[2] Wuxi AppTec Wuhan Co Ltd, Wuhan 430075, Hubei, Peoples R China

[3] Wuxi AppTec Shanghai Co Ltd, Shanghai 200131, Peoples R China

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2023年 / 14卷 / 10期

关键词：

KRAS; G12D selective inhibitor; ERAS-5024; SBDD; PDAC; anti-tumor efficacy;

D O I：

10.1021/acsmedchemlett.3c00245

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

KRAS G12D mutation has been found in approximately 45% of pancreatic ductal adeno-carcinoma (PDAC) cases, making it an attractive therapeutic target. Through structure-based drug design, a series of potent and selective KRAS G12D inhibitors were designed. The lead compound, ERAS-5024, inhibited ERK1/2 phosphorylation and cell proliferation in three-dimensional Cell-Titer Glo assays in AsPC-1 PDAC cells with single-digit nanomolar potency and caused tumor regression in the in vivo efficacy studies. We describe here the details of the design and synthesis program that led to the discovery of ERAS-5024.

引用

页码：1351 / 1357

页数：7

共 50 条

[31] MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors
Lakhani, Nehal J.
Melisi, Davide
Subbiah, Vivek
Ammakkanavar, Natraj Reddy
O'Reilly, Eileen M.
Cassier, Philippe Alexandre
Wainberg, Zev A.
Duffy, Austin G.
Patnaik, Amita
Fujiwara, Yutaka
Oberstein, Paul Eliezer
Garcia-Carbonero, Rocio
Wright, Jennifer
Lin, Aimee K.
Li, Jian
Axelson, Michael D.
Garrido-Laguna, Ignacio
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS845 - TPS845
[32] Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation
Wu, Shuang
Liao, Min
Li, Minxiong
Sun, Mingming
Xi, Ning
Zeng, Youlin
RSC MEDICINAL CHEMISTRY, 2022, 13 (10): : 1246 - 1264
[33] Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors
Barsanti, Paul A.
Pan, Yue
Lu, Yipin
Jain, Rama
Cox, Matthew
Aversa, Robert J.
Dillon, Michael P.
Ening, Robert
Hu, Cheng
Jin, Xianming
Knapp, Mark
Lan, Jiong
Ramurthy, Savithri
Rudewicz, Patrick
Setti, Lina
Subramanian, Sharadha
Mathur, Michelle
Taricani, Lorena
Thomas, George
Xiao, Linda
Yue, Qin
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (01): : 42 - 46
[34] Structure-Based Design of 2-Aminopyridine Oxazolidinones as Potent and Selective Tankyrase Inhibitors
Huang, Hongbing
Guzman-Perez, Angel
Acquaviva, Lisa
Berry, Virginia
Bregman, Howard
Dovey, Jennifer
Gunaydin, Hakan
Huang, Xin
Huang, Liyue
Saffran, Doug
Serafino, Randy
Schneider, Steve
Wilson, Cindy
DiMauro, Erin F.
ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (12): : 1218 - 1223
[35] Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3
Boyd, Scott
Brookfield, Joanna L.
Critchlow, Susan E.
Cumming, Iain A.
Curtis, Nicola J.
Debreczeni, Judit
Degorce, Sebastien L.
Donald, Craig
Evans, Nicola J.
Groombridge, Sam
Hopcroft, Philip
Jones, Neil P.
Kettle, Jason G.
Lamont, Scott
Lewis, Hilary J.
MacFaull, Philip
McLoughlin, Sheila B.
Rigoreau, Laurent J. M.
Smith, James M.
St-Gallay, Steve
Stock, Julie K.
Turnbull, Andrew P.
Wheatley, Edward R.
Winter, Jon
Wingfield, Jonathan
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (08) : 3611 - 3625
[36] Structure-based design of highly potent and selective Cdk4 inhibitors.
Honma, T
Hayashi, K
Yoshizumi, T
Ikeura, C
Ikuta, M
Suzuki-Takahashi, I
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U437 - U438
[37] Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine
Waldschmidt, Helen V.
Homan, Kristoff T.
Cato, Marilyn C.
Cruz-Rodriguez, Osvaldo
Cannavo, Alessandro
Wilson, Michael W.
Song, Jianliang
Cheung, Joseph Y.
Koch, Walter J.
Tesmer, John J. G.
Larsen, Scott D.
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (07) : 3052 - 3069
[38] Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors
Oh, M
Im, I
Lee, YJ
Kim, YH
Yoon, JH
Park, HG
Higashiyama, S
Kim, YC
Park, WJ
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (24) : 6071 - 6074
[39] Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors
Sun, Ran
Hu, Yangfan
Liu, Xiangwen
Lin, Yingjun
Lv, Dan
Li, Wei
Fu, Lei
Jiang, Faqin
BIOORGANIC CHEMISTRY, 2024, 148
[40] Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Kale, Ramesh
Samant, Charudatt
Nandakumar, Krishnadas
Pai, K. Sreedhara Ranganath
Bhonde, Mandar
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 760

← 1 2 3 4 5 →